KarMMa-2
A Phase 2, Multi-Cohort, Copen-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with Clinical High-Risk Multiple Myeloma (KARMMA-2)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 265 patients (estimated)
- Sponsors
- Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb
- Tags
- CAR T Cell, B-Cell Maturation Antigen (BCMA), High Risk
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 959
- NCT Identifier
- NCT03601078
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.